Ocular Hypertension Epidemiology Forecast Report 2021-2030 - ResearchAndMarkets.com
The "Ocular Hypertension - Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
This 'Ocular Hypertension (OHT)-Epidemiology Forecast - 2030' report delivers an in-depth understanding of the Ocular Hypertension (OHT), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Ocular Hypertension (OHT) Epidemiology
The Ocular Hypertension (OHT) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Ocular Hypertension (OHT) epidemiology segmented as the Prevalent cases of Ocular Hypertension , Gender-specific prevalent case of Ocular Hypertension, Age-specific prevalent cases of Ocular Hypertension and Treated- cases of Ocular Hypertension.
The report includes the prevalent scenario of Ocular Hypertension (OHT) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Country Wise- Ocular Hypertension (OHT) Epidemiology
The epidemiology segment also provides the Ocular Hypertension (OHT) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total Prevalent population of Ocular Hypertension (OHT) Associated in 7MM countries was estimated to be 20,817,647 cases in 2020 and expected to increase at a CAGR of 0.64 % for the study period i.e. 2018-2030.
- As per the estimates, US has the highest prevalent population of Ocular Hypertension (OHT) with 8,772,815 prevalent cases in 2020.
Among the EU5 countries, Germany had the highest prevalent population of Ocular Hypertension (OHT). On the other hand, Spain had the lowest number of prevalent cases in 2020.
Scope of the Report
- Ocular Hypertension (OHT) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
- Ocular Hypertension(OHT) Epidemiology Report and Model provide an overview of the risk factors and global trends of Ocular Hypertension (OHT) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight into the historical and forecasted patient pool of Ocular Hypertension (OHT) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps recognize the growth opportunities in the 7MM concerning the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Ocular Hypertension (OHT)
- The report provides the segmentation of the Ocular Hypertension (OHT) epidemiology by Prevalent Cases of Ocular Hypertension (OHT) in 7MM
- The report provides the segmentation of the Ocular Hypertension (OHT) epidemiology by Age-specific Prevalent Cases of Ocular Hypertension (OHT) in 7MM
Key Topics Covered:
1 Key Insights
2 Report Introduction
3 Ocular Hypertension Epidemiology Overview at a Glance
3.1 Patient Share (%) Distribution of Ocular Hypertension in 2018
3.2 Patient Share (%) Distribution of Ocular Hypertension in 2030
4 Executive Summary of Ocular Hypertension
5 Disease Background and Overview
5.1 Introduction
5.2 Causes
5.3 Physiology and pathogenesis
5.4 Morphology
5.5 Diagnosis
6 Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total Prevalent Patient Population of OHT
6.3 Assumption and Rationale
6.4 The United States
6.4.1 Prevalent Cases of Ocular Hypertension in the United States
6.4.2 Gender-specific Prevalence of Ocular Hypertension in the United States
6.4.3 Age-specific Prevalence of Ocular Hypertension in the United States
6.4.4 Treated cases of Ocular Hypertension in the United States
6.5 EU5
6.5.1 Germany
6.5.2 France
6.5.3 Italy
6.5.4 Spain
6.5.5 United Kingdom
6.6 Japan
7 Treatment
7.1 Frequency and follow-up
7.2 Uncertainties regarding best practice for managing ocular hypertension
7.3 Progression to Glaucoma
8 NICE Recommendations and Guidelines
8.1 Case-finding
8.2 Diagnosis
8.3 Standard practice for all assessments
8.4 Reassessment tests
8.5 Treatment
8.6 Stopping treatment for people with OHT or suspected POAG
9 Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/xi9ysp
News published on and distributed by:
